% | $
Quotes you view appear here for quick access.

Momenta Pharmaceuticals Inc. Message Board

  • pump_killer pump_killer Nov 1, 2012 7:52 AM Flag



    This Goldmine has BRUTAL upside potential because Ampligen will be the first Drug which could get approval for Chronic Fatigue Syndrome .
    There are 4 Million CFS Patients in USA alone a treatment with Ampligen will cost between $30000-50000 means the Drug has MULTI BILLION DOLLAR POTENTIAL .

    You can play the Runup to Decision if you dont like to hold trough the decision Its a win win situation from current bargain level . Heb could run to $3 before ADCOM meeting like in 2009 .

    My Target is $2-3 before Decision and $7++ after FDA approval . GLTA

    Hemispherx (HEB)

    MarketCap : $120 M
    Cash : $38 M

    Price: $0.7

    Oct. 22, 2012 -- Hemispherx Biopharma, today announced that the U.S. Food and Drug Administration ("FDA") has scheduled for December 20, 2012 a meeting of the Arthritis Advisory Committee ("AAC") to discuss the Ampligen(R) New Drug Application for Chronic Fatigue Syndrome ("CFS") which is currently under review by the FDA. As previously announced, the Prescription Drug User Fee Act ("PDUFA") review goal for the FDA to complete its review is February 2, 2013.

    This topic is deleted.
12.20-0.51(-4.01%)Aug 26 4:00 PMEDT